Terms: = Breast cancer AND TPM4, P67936, 7171, ENSG00000167460 AND Treatment
4 results:
1. Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition.
Tian J; Wang V; Wang N; Khadang B; Boudreault J; Bakdounes K; Ali S; Lebrun JJ
Breast Cancer Res; 2021 Feb; 23(1):23. PubMed ID: 33588911
[TBL] [Abstract] [Full Text] [Related]
2. Comparative proteomics of primary breast carcinomas and lymph node metastases outlining markers of tumor invasion.
Milioli HH; Santos Sousa K; Kaviski R; Dos Santos Oliveira NC; De Andrade Urban C; De Lima RS; Cavalli IJ; De Souza Fonseca Ribeiro EM
Cancer Genomics Proteomics; 2015; 12(2):89-101. PubMed ID: 25770193
[TBL] [Abstract] [Full Text] [Related]
3. A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer.
Mihály Z; Kormos M; Lánczky A; Dank M; Budczies J; Szász MA; Győrffy B
Breast Cancer Res Treat; 2013 Jul; 140(2):219-32. PubMed ID: 23836010
[TBL] [Abstract] [Full Text] [Related]
4. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen.
Mendes-Pereira AM; Sims D; Dexter T; Fenwick K; Assiotis I; Kozarewa I; Mitsopoulos C; Hakas J; Zvelebil M; Lord CJ; Ashworth A
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2730-5. PubMed ID: 21482774
[TBL] [Abstract] [Full Text] [Related]
